No Cover Image

Journal article 1089 views 134 downloads

Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy

Laith Alrubaiy Orcid Logo, Rafid Sikafi Orcid Logo, Hayley Hutchings Orcid Logo, Ian Arnott, John Williams

Clinics and Practice, Volume: 12, Issue: 3, Pages: 436 - 448

Swansea University Authors: Laith Alrubaiy Orcid Logo, Hayley Hutchings Orcid Logo, John Williams

  • clinpract-12-00048.pdf

    PDF | Version of Record

    Copyright: © 2022 by the authors. This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

    Download (268.97KB)

Check full text

DOI (Published version): 10.3390/clinpract12030048

Abstract

Background: Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 tha...

Full description

Published in: Clinics and Practice
ISSN: 2039-7283
Published: MDPI AG 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60169
first_indexed 2022-06-09T09:12:43Z
last_indexed 2023-01-11T14:41:57Z
id cronfa60169
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-07-06T12:05:23.8333468</datestamp><bib-version>v2</bib-version><id>60169</id><entry>2022-06-09</entry><title>Further Validation of the Crohn&#x2019;s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy</title><swanseaauthors><author><sid>62b59abd526b328bbb125dfaa9bdcd6d</sid><ORCID>0000-0002-6340-8244</ORCID><firstname>Laith</firstname><surname>Alrubaiy</surname><name>Laith Alrubaiy</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>bdf5d5f154d339dd92bb25884b7c3652</sid><ORCID>0000-0003-4155-1741</ORCID><firstname>Hayley</firstname><surname>Hutchings</surname><name>Hayley Hutchings</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>911a5c03419acf47eab0844e2cd5ab7f</sid><firstname>John</firstname><surname>Williams</surname><name>John Williams</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-06-09</date><abstract>Background: Crohn&#x2019;s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 that would be suitable for patients with a stoma. Methods: Baseline data were collected from a cohort of patients with acute ulcerative colitis who were participating in the CONSTRUCT multicentre clinical trial. A subset of the CUCQ-32 questions was selected by stepwise regression. Further validation was examined using data from the UK IBD biological therapies audit. Construct validity was carried out using the EuroQol 5 dimensions (EQ5D) questionnaire, Simple Clinical Colitis Activity Index (SCCAI), and the Harvey&#x2013;Bradshaw Index (HBI). Results: Using the data from 124 patients, a short-version questionnaire (CUCQ-12) was developed. Data from 484 patients with IBD (382 patients with Crohn&#x2019;s disease, 76 patients with ulcerative colitis, and 26 patients with IBD-Unclassified) and 61 patients with stoma provided further validation of the CUCQ-12. A literature review and an expert focus group identified supplementary stoma-specific questions for the CUCQ-12+. The CUCQ-12+ demonstrated excellent internal consistency (Cronbach&#x2019;s &#x3B1; = 0.86); established effective reproducibility (intra-class correlation coefficient = 0.74); correlated well with the EQ5D (r= &#x2212;0.48), HBI (r = 0.45), and SCCAI (r = 0.43); and represented good responsiveness statistics (&gt;0.5). Conclusions: CUCQ-12+ is a valid and reliable QoL measure used for all patients with IBD in clinical practice, including patients with a stoma.</abstract><type>Journal Article</type><journal>Clinics and Practice</journal><volume>12</volume><journalNumber>3</journalNumber><paginationStart>436</paginationStart><paginationEnd>448</paginationEnd><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2039-7283</issnElectronic><keywords>quality of life; Inflammatory Bowel Disease; Crohn&#x2019;s disease; ulcerative colitis; Patients Reported Outcomes</keywords><publishedDay>10</publishedDay><publishedMonth>6</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-06-10</publishedDate><doi>10.3390/clinpract12030048</doi><url/><notes>The data presented in this study are available on request from the corresponding author.</notes><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><apcterm>Not Required</apcterm><funders>This research received no external funding.</funders><lastEdited>2022-07-06T12:05:23.8333468</lastEdited><Created>2022-06-09T10:08:14.8263545</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Laith</firstname><surname>Alrubaiy</surname><orcid>0000-0002-6340-8244</orcid><order>1</order></author><author><firstname>Rafid</firstname><surname>Sikafi</surname><orcid>0000-0002-4701-6953</orcid><order>2</order></author><author><firstname>Hayley</firstname><surname>Hutchings</surname><orcid>0000-0003-4155-1741</orcid><order>3</order></author><author><firstname>Ian</firstname><surname>Arnott</surname><order>4</order></author><author><firstname>John</firstname><surname>Williams</surname><order>5</order></author></authors><documents><document><filename>60169__24276__a4ef5e6c1b5c4a0c9130bc2fb6df3e41.pdf</filename><originalFilename>clinpract-12-00048.pdf</originalFilename><uploaded>2022-06-10T15:03:36.4897088</uploaded><type>Output</type><contentLength>275427</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright: &#xA9; 2022 by the authors. This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-07-06T12:05:23.8333468 v2 60169 2022-06-09 Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy 62b59abd526b328bbb125dfaa9bdcd6d 0000-0002-6340-8244 Laith Alrubaiy Laith Alrubaiy true false bdf5d5f154d339dd92bb25884b7c3652 0000-0003-4155-1741 Hayley Hutchings Hayley Hutchings true false 911a5c03419acf47eab0844e2cd5ab7f John Williams John Williams true false 2022-06-09 Background: Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 that would be suitable for patients with a stoma. Methods: Baseline data were collected from a cohort of patients with acute ulcerative colitis who were participating in the CONSTRUCT multicentre clinical trial. A subset of the CUCQ-32 questions was selected by stepwise regression. Further validation was examined using data from the UK IBD biological therapies audit. Construct validity was carried out using the EuroQol 5 dimensions (EQ5D) questionnaire, Simple Clinical Colitis Activity Index (SCCAI), and the Harvey–Bradshaw Index (HBI). Results: Using the data from 124 patients, a short-version questionnaire (CUCQ-12) was developed. Data from 484 patients with IBD (382 patients with Crohn’s disease, 76 patients with ulcerative colitis, and 26 patients with IBD-Unclassified) and 61 patients with stoma provided further validation of the CUCQ-12. A literature review and an expert focus group identified supplementary stoma-specific questions for the CUCQ-12+. The CUCQ-12+ demonstrated excellent internal consistency (Cronbach’s α = 0.86); established effective reproducibility (intra-class correlation coefficient = 0.74); correlated well with the EQ5D (r= −0.48), HBI (r = 0.45), and SCCAI (r = 0.43); and represented good responsiveness statistics (>0.5). Conclusions: CUCQ-12+ is a valid and reliable QoL measure used for all patients with IBD in clinical practice, including patients with a stoma. Journal Article Clinics and Practice 12 3 436 448 MDPI AG 2039-7283 quality of life; Inflammatory Bowel Disease; Crohn’s disease; ulcerative colitis; Patients Reported Outcomes 10 6 2022 2022-06-10 10.3390/clinpract12030048 The data presented in this study are available on request from the corresponding author. COLLEGE NANME COLLEGE CODE Swansea University Not Required This research received no external funding. 2022-07-06T12:05:23.8333468 2022-06-09T10:08:14.8263545 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Laith Alrubaiy 0000-0002-6340-8244 1 Rafid Sikafi 0000-0002-4701-6953 2 Hayley Hutchings 0000-0003-4155-1741 3 Ian Arnott 4 John Williams 5 60169__24276__a4ef5e6c1b5c4a0c9130bc2fb6df3e41.pdf clinpract-12-00048.pdf 2022-06-10T15:03:36.4897088 Output 275427 application/pdf Version of Record true Copyright: © 2022 by the authors. This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license true eng https://creativecommons.org/licenses/by/4.0/
title Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
spellingShingle Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
Laith Alrubaiy
Hayley Hutchings
John Williams
title_short Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
title_full Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
title_fullStr Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
title_full_unstemmed Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
title_sort Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy
author_id_str_mv 62b59abd526b328bbb125dfaa9bdcd6d
bdf5d5f154d339dd92bb25884b7c3652
911a5c03419acf47eab0844e2cd5ab7f
author_id_fullname_str_mv 62b59abd526b328bbb125dfaa9bdcd6d_***_Laith Alrubaiy
bdf5d5f154d339dd92bb25884b7c3652_***_Hayley Hutchings
911a5c03419acf47eab0844e2cd5ab7f_***_John Williams
author Laith Alrubaiy
Hayley Hutchings
John Williams
author2 Laith Alrubaiy
Rafid Sikafi
Hayley Hutchings
Ian Arnott
John Williams
format Journal article
container_title Clinics and Practice
container_volume 12
container_issue 3
container_start_page 436
publishDate 2022
institution Swansea University
issn 2039-7283
doi_str_mv 10.3390/clinpract12030048
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Background: Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 that would be suitable for patients with a stoma. Methods: Baseline data were collected from a cohort of patients with acute ulcerative colitis who were participating in the CONSTRUCT multicentre clinical trial. A subset of the CUCQ-32 questions was selected by stepwise regression. Further validation was examined using data from the UK IBD biological therapies audit. Construct validity was carried out using the EuroQol 5 dimensions (EQ5D) questionnaire, Simple Clinical Colitis Activity Index (SCCAI), and the Harvey–Bradshaw Index (HBI). Results: Using the data from 124 patients, a short-version questionnaire (CUCQ-12) was developed. Data from 484 patients with IBD (382 patients with Crohn’s disease, 76 patients with ulcerative colitis, and 26 patients with IBD-Unclassified) and 61 patients with stoma provided further validation of the CUCQ-12. A literature review and an expert focus group identified supplementary stoma-specific questions for the CUCQ-12+. The CUCQ-12+ demonstrated excellent internal consistency (Cronbach’s α = 0.86); established effective reproducibility (intra-class correlation coefficient = 0.74); correlated well with the EQ5D (r= −0.48), HBI (r = 0.45), and SCCAI (r = 0.43); and represented good responsiveness statistics (>0.5). Conclusions: CUCQ-12+ is a valid and reliable QoL measure used for all patients with IBD in clinical practice, including patients with a stoma.
published_date 2022-06-10T04:59:04Z
_version_ 1851730212907122688
score 11.090464

Similar Items